TOWARDS BETTER COORDINATION AND MORE EFFICIENT PATIENT PATHWAYS IN COPD
Author(s)
Devillier P1, Dorizon D2, Nachbaur G2, Hudry J2, Antoun Z2
1UPRES EA220, Hôpital Foch, Suresnes, France, 2GlaxoSmithkline, Marly le roi, France
OBJECTIVES: Within a challenging French healthcare system, where a coordinated patient pathway would address needs of patients, healthcare professionals (HP) and payers, the study aims to identify concrete, sustainable and incentive solutions to optimise COPD pathways efficiency. METHODS: A multidisciplinary team identified and prioritized measures to improve COPD pathway management. For each measure, costs for implementation, healthcare savings (including hospitalization) and the return on investment (ROI) were estimated based on published works conducted in COPD in France when available, in other chronic diseases or countries otherwise. These estimates accounted for the targeted COPD population, the acceptance and adherence rates and ranges were set when several references were available. ROI for combinations of measures was also computed with a weighted impact on gains while costs were summed up. RESULTS: The prioritized measures were M1) Reinforcing interprofessional/HP-patient coordination via hospital/ambulatory coordinators and platforms for information exchange; M2) Encouraging pulmonary rehabilitation with physiotherapists’ home visits or phone coaching ; M3) Promoting community-based therapeutic patient education via HPs (additional training, fees) and e-learning; M4) Providing patients with individual monitoring using mobile applications, devices connected to telemedicine, pharmaceutical consultations, disease management programs; M5) Motivating patients with pedometers, sport club membership or smoking cessation financial support. A high ROI (2.2–12.5) was obtained for M1 with reinforced coordination for stage ¾ COPD with a saving of 1634-7145€/ patient/ year and platform use (ROI: 1.8). The average ROI for M2, M3, M4, M5 was respectively 10, 5.4, 2.4 and 2.5. Overall costs of implementation were estimated at 335-435 MEuros (2.8-3.7% COPD costs). A combination of the more effective measures of M1/M2/M4/M5 lead to a combined ROI 1.97 -6.67. CONCLUSIONS: Funding of the solutions would represent less than 5% increase in disease management cost offset by the savings expected from a more efficient organization.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PHS42
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Respiratory-Related Disorders